Advertisement

Rheumatology International

, Volume 30, Issue 12, pp 1565–1570 | Cite as

Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China

  • Jijun Zhao
  • Minli Qiu
  • Meirong Li
  • Caisheng LuEmail author
  • Jieruo Gu
Original Article

Abstract

To investigate the prevalence of hepatitis B virus (HBV) infection in systemic lupus erythematosus (SLE) patients in southern China, SLE inpatients were retrospectively investigated for their HBV infection rate. Fifteen SLE patients positive for hepatitis B surface antigen (HBsAg) were followed up. Furthermore, serum interferon (IFN)-α levels among SLE patients were detected by ELISA. Results showed estimated HBsAg-positive rate was 10.74% in general population. The HBsAg-positive rate was lower in SLE patients compared with controls (2.33 vs. 9.57%, P < 0.01). Interestingly, 13 out of 15 SLE patients converted from HBsAg positive to HBV surface antibody (HBsAb) positive even under glucocorticoid therapy. In addition, we found significantly increased IFN-α levels in SLE patients.The prevalence of HBV infection in SLE patients was lower than that in sex- and age-matched non-SLE controls in southern China. The characteristic IFN signatures in SLE may favor the subsequent clearance of HBV.

Keywords

Systemic lupus erythematosus Hepatitis B virus Prevalence Interferons 

Notes

Acknowledgments

This study was supported by Grant no. 30571736/C0302050301 from the National Natural Science Foundation of China (NSFC) and Science and Technology Planning Project of Guangdong Province, China (No. 2006B35601003)

References

  1. 1.
    Lau GK (2001) Hepatitis B infection in China. Clin Liver Dis 5:361–379CrossRefPubMedGoogle Scholar
  2. 2.
    Qu JB, Zhang ZW, Shimbo S et al (2000) Urban–rural comparison of HBV and HCV infection prevalence in Eastern China. Biomed Environ Sci 13:243–253PubMedGoogle Scholar
  3. 3.
    Wen YM (2001) Laboratory diagnosis of viral hepatitis in China: the present and the future. Clin Chem Lab Med 39:1183–1189CrossRefPubMedGoogle Scholar
  4. 4.
    Alarcon-Segovia D, Fishbein E (1971) Australia antigen in systemic lupus. N Engl J Med 284:448PubMedGoogle Scholar
  5. 5.
    Ziegenfuss JF Jr, Byrne EB, Stoloff IL, Burka ER (1972) Australia antigen in systemic lupus erythematosus. Lancet 1:800CrossRefPubMedGoogle Scholar
  6. 6.
    Bonafede RP, van Staden M, Klemp P (1986) Hepatitis B virus infection and liver function in patients with systemic lupus erythematosus. J Rheumatol 13:1050–1052PubMedGoogle Scholar
  7. 7.
    Shorey J, Cheatum DE, Combes B, Ziff M (1974) Hepatitis B antigen and antibody in patients with systemic lupus erythematosus. Arthritis Rheum 17:583–589CrossRefPubMedGoogle Scholar
  8. 8.
    Permin H, Aldershvile J, Nielsen JO (1982) Hepatitis B virus infection in patients with rheumatic diseases. Ann Rheum Dis 41:479–482CrossRefPubMedGoogle Scholar
  9. 9.
    Mac-Moune Lai F, Lai KN, Lee JC, Hom BL (1987) Hepatitis B virus-related glomerulopathy in patients with systemic lupus erythematosus. Am J Clin Pathol 88:412–420PubMedGoogle Scholar
  10. 10.
    Lai KN, Lai FM, Lo S, Leung A (1987) Is there a pathogenetic role of hepatitis B virus in lupus nephritis? Arch Pathol Lab Med 111:185–188PubMedGoogle Scholar
  11. 11.
    Staples PJ, Gerding DN, Decker JL et al (1974) Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 17:110CrossRefGoogle Scholar
  12. 12.
    Watanabe Duffy KN, Duffy CM et al (1991) Infection and disease activity in SLE: a review of hospitalized patients. J Rheumatol 18:1180–1184Google Scholar
  13. 13.
    Boumpas DT, Paliogianni F, Anastassiou ED et al (1991) Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 9:413–423PubMedGoogle Scholar
  14. 14.
    McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K (1992) Frequency of adverse reactions to hepatitis B vaccine in 43, 618 persons. Am J Med 92:254–256CrossRefPubMedGoogle Scholar
  15. 15.
    Bracci M, Zoppini A (1997) Polyarthritis associated with hepatitis B vaccination. Br J Rheumatol 36:300–301CrossRefPubMedGoogle Scholar
  16. 16.
    Tudela P, Marti S, Bonal J (1992) Systemic lupus erythematosus and vaccination against hepatitis B. Nephron 62:236CrossRefPubMedGoogle Scholar
  17. 17.
    Fritz M, Vats K, Goyal RK (2005) Neonatal lupus and IUGR following alpha-interferon therapy during pregnancy. J Perinatol 25:552–554CrossRefPubMedGoogle Scholar
  18. 18.
    Venkataseshan VS, Lieberman K, Kim DU, Thung SN, Dikman S, D’Agati V et al (1990) Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore) 69:200–216Google Scholar
  19. 19.
    Lai FM, To KF, Wang AY et al (2000) Hepatitis B virus-related nephropathy and lupus nephritis: morphologic similarities of two clinical entities. Mod Pathol 13:166–172CrossRefPubMedGoogle Scholar
  20. 20.
    Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201–208CrossRefPubMedGoogle Scholar
  21. 21.
    Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H (2006) TLR7 ligands induce higher IFN-alpha production in females. J Immunol 177:2088–2096PubMedGoogle Scholar
  22. 22.
    Koutouzov S, Mathian A, Dalloul A (2006) Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 5:554–562CrossRefPubMedGoogle Scholar
  23. 23.
    Pascual V, Farkas L, Banchereau J (2006) Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18:676–682CrossRefPubMedGoogle Scholar
  24. 24.
    Lafyatis R, York M, Marshak-Rothstein A (2006) Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 54:3068–3070CrossRefPubMedGoogle Scholar
  25. 25.
    Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383–392CrossRefPubMedGoogle Scholar
  26. 26.
    Feng X, Wu H, Grossman JM et al (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54:2951–2962CrossRefPubMedGoogle Scholar
  27. 27.
    Looi LM, Prathap K (1982) Hepatitis B virus surface antigen in glomerular immune complex deposits of patients with systemic lupus erythematosus. Histopathology 6:141–147CrossRefPubMedGoogle Scholar
  28. 28.
    Santoro D, Stella M, Montalto G, Castellino S (2007) Lupus nephritis after hepatitis B vaccination: an uncommon complication. Clin Nephrol 67:61–63PubMedGoogle Scholar
  29. 29.
    Finielz P, Lam-Kam-Sang LF, Guiserix J (1998) Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant 13:2420–2421CrossRefPubMedGoogle Scholar
  30. 30.
    Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365CrossRefPubMedGoogle Scholar
  31. 31.
    Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB (2004) IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172:6476–6481PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jijun Zhao
    • 1
  • Minli Qiu
    • 1
  • Meirong Li
    • 1
  • Caisheng Lu
    • 1
    Email author
  • Jieruo Gu
    • 1
  1. 1.Department of Rheumatology, Third Affiliated HospitalSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations